LCLA.F PT Kalbe Farma Tbk
- Market cap
- EUR 1.33B
- P/E
- -
- P/B
- 1.13x
- ROE
- 14.5%
- Dividend yield
- 3.38%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LCLA.F undervalued?
Graham numberThe Graham number of PT Kalbe Farma Tbk cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PT Kalbe Farma Tbk fundamental analysis
No fundamental analysis for PT Kalbe Farma Tbk yet.
PT Kalbe Farma Tbk stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PT Kalbe Farma Tbk
PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In…
Full company profilePT Kalbe Farma Tbk financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PT Kalbe Farma Tbk annual financial statements (IDR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 19.4T | 20.2T | 21.1T | 22.6T | 23.1T | 26.3T | 28.9T | 30.4T | 32.6T | 35.3T | 38.6T |
| Gross Profit | 9.47T | 9.79T | 9.82T | 10.1T | 10.2T | 11.3T | 11.7T | 11.8T | 13.0T | 14.1T | 14.5T |
| Operating Income | 3.11T | 3.24T | 3.29T | 3.30T | 3.55T | 4.00T | 4.22T | 3.63T | 4.07T | 4.55T | 4.59T |
| EBITDA | - | 3.55T | 3.61T | 3.70T | 4.04T | 4.54T | 4.83T | 4.02T | 4.60T | 5.18T | 5.20T |
| Net Income | 2.30T | 2.40T | 2.46T | 2.51T | 2.73T | 3.18T | 3.38T | 2.77T | 3.24T | 3.66T | 3.65T |
| EPS | - | 51 | 52 | 53 | 58 | 68 | 73 | 60 | 71 | 81 | 81 |
| Balance Sheet | |||||||||||
| Total Assets | 15.2T | 16.6T | 18.1T | 20.3T | 22.6T | 25.7T | 27.2T | 27.1T | 29.4T | 30.7T | 33.4T |
| Total Liabilities | 2.76T | 2.72T | 2.85T | 3.56T | 4.29T | 4.40T | 5.14T | 3.94T | 4.84T | 5.97T | 6.82T |
| Shareholders' Equity | 11.9T | 13.3T | 14.6T | 15.9T | 17.4T | 19.6T | 20.4T | 21.4T | 22.8T | 23.3T | 25.1T |
| Cash & Short-term Investments | 2.90T | 2.78T | 3.15T | 3.04T | 5.21T | 6.22T | 3.95T | 3.23T | 4.72T | 4.33T | 5.42T |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.16T | 2.01T | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | 1.04T | 1.16T | 1.37T | 1.98T | 1.12T | 1.00T | 870B | 1.18T | 1.25T | 810B | 864B |
| Free Cash Flow | - | 773B | 1.40T | 520B | 3.10T | 1.83T | 402B | 1.73T | 3.53T | 2.46T | 2.65T |
| Ratios | |||||||||||
| ROE | 19.3% | 18.1% | 16.8% | 15.8% | 15.7% | 16.3% | 16.6% | 12.9% | 14.2% | 15.7% | 14.5% |
| ROA | 15.1% | 14.5% | 13.5% | 12.4% | 12.1% | 12.4% | 12.4% | 10.2% | 11.0% | 11.9% | 10.9% |
| Net Profit Margin | 11.9% | 11.9% | 11.7% | 11.1% | 11.8% | 12.1% | 11.7% | 9.1% | 9.9% | 10.4% | 9.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PT Kalbe Farma Tbk dividends
- Dividend yield
- 3.38%
- Forward dividend
- -
- Payout ratio
- 44.6%
- Ex-dividend date
- Jun 4, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | IDR 1.64T | 36 | 44.6% |
| 2024 | IDR 1.43T | 31 | 44.2% |
| 2023 | IDR 1.76T | 38 | 63.5% |
| 2022 | IDR 1.63T | 35 | 48.2% |
| 2021 | IDR 1.31T | 28 | 41.2% |
| 2020 | IDR 1.22T | 26 | 44.6% |
| 2019 | IDR 1.25T | 27 | 50.0% |
| 2018 | IDR 1.19T | 25 | 48.5% |
| 2017 | EUR 1.03T | 22 | 42.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Oct 8, 2012.
Who owns PT Kalbe Farma Tbk
- Insiders 64.98%
- Institutions 11.66%
- Public & others 23.36%
- Shares outstanding 45.2B
- Free float 17.8B
PT Kalbe Farma Tbk company profile
- Company name
- PT Kalbe Farma Tbk
- Ticker
- LCLA.F
- ISIN
- ID1000125107
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Metals & Mining
- Employees
- 12,726
- Fiscal year end
- December
- Address
- Gedung KALBE, Jakarta, Indonesia, 10510
- Phone
- 62 21 4287 3888
- Website
- kalbe.co.id
About PT Kalbe Farma Tbk
PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. The company was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
PT Kalbe Farma Tbk management
4- Ms. Bernadette Ruth Irawati Setiady MSc.President Director · born 1962
- Mr. Sie DjohanDirector of Corporate Business Development, Management System & Regulatory Affairs and Director · born 1967
- Mr. Rustam TanHead of Internal Audit Unit · born 1970
- Maria Teresa FabiolaCorporate Secretary · born 1972